[Removal ability of IgG anti-GQ1b antibody in immunoadsorption therapy for Fisher syndrome--comparison of the removal ability between tryptophane column and phenylalanine column].
Anti-GQ1b antibody seems to be a pathogenetic factor in the development of Fisher syndrome (FS). Although several patients received immunoadsorption therapy (IAT), whether it can remove the autoantibody has not yet been clarified. We treated two patients with FS by IAT using tryptophane column (TR-C) and phenylalanine column (PH-C) (TR-C; 9 times altogether in 2 patients, PH-C: twice altogether in 2 patients), and compared the removal ability of IgG anti-GQ1b antibody and immunoglobulin between TR-C and PH-C. TR-C removed the IgG anti-GQ1b antibodies, IgG, IgA and IgM more than PH-C did. TR-C removed the IgG anti-GQ1b antibody more selectively than non-specific immunoglobulin. In practicing IAT on FS, the use of TR-C rather than PH-C is recommended in view of the removal ability of the autoantibody.
Ichikawa
H
H
Department of Neurology, Showa University School of Medicine.
Suzuki
M
M
Kawamura
M
M
Sugita
K
K
Watanabe
Y
Y
Yuki
N
N
D000328:Adult; D001323:Autoantibodies / Q000302:isolation & purification*; D002524:Cerebellar Ataxia / Q000628:therapy; D005260:Female; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000302:isolation & purification*; D007163:Immunosorbent Techniques; D009886:Ophthalmoplegia / Q000628:therapy*; D010649:Phenylalanine; D011129:Polyradiculoneuropathy / Q000628:therapy*; D012021:Reflex, Abnormal; D013577:Syndrome; D014364:Tryptophan
D001323:Autoantibodies; D005732:Gangliosides; D007074:Immunoglobulin G; D010649:Phenylalanine; C039129:GQ1b ganglioside; D014364:Tryptophan